All In MedTech

Device Trial Radar · NCT07931300

Multicenter Study of SIS Patch in High-risk Colorectal Anastomosis

Multicenter Real-world Study of SIS Reinforcement Patch in High-risk Colorectal Anastomosis and Exploration of the Mechanism Promoting Anastomotic Healing

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

255

Planned (sponsor's estimate)

Start

Jan 1, 2025

Primary completion

Jun 30, 2027

Study completion Sep 30, 2027

Sponsor

Lead sponsor
Beijing Chao Yang HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
China-Japan Friendship Hospital; Zhongnan Hospital; Henan Provincial People's Hospital; Zhoukou Central Hospital; Sixth Affiliated Hospital, Sun Yat-sen University; People's Hospital of Guangxi Zhuang Autonomous Region; The First Affiliated Hospital of BaoTou Medical College
First posted
Nov 12, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety and effectiveness of Small Intestinal Submucosa (SIS) material used for anastomotic reinforcement in patients with high-risk factors for colorectal cancer to prevent anastomotic leakage. It will also explore the molecular biological mechanism of SIS/polycaprolactone-acrylic acid (PCA) patches in promoting tissue regeneration and verify the biological versatility of the new SIS/PCA patches at the cellular level. The main questions it aims to answer is: Can the use of SIS reinforcement patches effectively reduce the incidence of anastomotic leakage in patients with high-risk colorectal anastomosis after surgery (within 1 month, 3 months, and 6 months of follow-up)? This is a single-arm, non-randomized, open-label, multi-center exploratory study. All eligible patients will be in the intervention group and receive SIS reinforcement patch for anastomosis during surgery; there is no control group for comparison. Participants will: Sign an informed consent form during the screening period (7 days before surgery) and provide basic clinical information, medical history, and undergo assessment against inclusion and exclusion criteria. Undergo gastrointestinal anastomosis using SIS reinforcement patches during surgery (Day 0 of the study), with intraoperative observation of the immediate stapling effect and recording of anastomotic conditions and complications. Complete follow-up visits at approximately 30 days, 90 days, and 180 days after surgery. During follow-up, they will undergo assessments of anastomotic leakage, healing status, adverse events, and effectiveness; they will also cooperate with the recording of concomitant medications/implanted devices and filling out of Case Report Forms (CRFs). Have their relevant perioperative indicators collected by researchers to evaluate the safety and effectiveness of the SIS material anastomotic reinforcement patch.

Conditions

  • Colorectal Cancer

Interventions

  • SIS Patch Intervention for High - Risk Colorectal AnastomosisDevice

    This intervention uses a Small Intestinal Submucosa (SIS) patch (a medical device) to reinforce anastomosis during gastrointestinal anastomosis surgery, targeting patients with high-risk factors for colorectal anastomotic leakage. Preoperatively, subjects are screened for high-risk factors (e.g., abdominopelvic abscess from gastrointestinal perforation, ulcerative colitis history, hormone therapy within 6 months, etc.). On Study Day 0 (surgery day), the SIS patch is applied during colorectal anastomosis, with intraoperative observation of immediate stapling effect (e.g., seromuscular dehiscence, bleeding). Postoperatively, subjects are followed up at 1, 3, 6 months to monitor anastomotic leakage, healing and adverse events. It differs from conventional anastomosis by focusing on high-risk populations, with intraoperative and long-term assessments to prevent anastomotic leakage.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Intraoperative Anastomotic Immediate Defect RateTime frame: Surgery day (intraoperative)
  2. 30-Day Anastomotic Leakage RateTime frame: 30 days post-surgery (Visit 2)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing chaoyang hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.